Annika Ehrlich
Family · San Francisco, CANPI 1568868479
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $81,629 of the $128,487 with a category attached, or 63.5%. AbbVie accounts for 80.6% of it on its own, with 10 other manufacturers making up the rest. 2025 is the largest year on record at $47,312, 2.5 times the $19,084 reported in 2021. Among family clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 273 payments — averaging $470.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$104K
- Lilly USA, LLC$11K
- Pfizer$5K
- Axsome Therapeutics, Inc.$4K
- Lundbeck LLC$3K
- Biodelivery Sciences International, Inc.$750
- plus $636 from 5 others
What the payments were for
- Consulting fees$28,24822%
- Speaking & faculty fees$81,62964%
- Grants$850%
- Travel & lodging$11,9099%
- Food & beverage$6,6025%
- Education$140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 228 | $103,508 |
| Lilly USA, LLC | 24 | $11,210 |
| Pfizer | 8 | $5,321 |
| Axsome Therapeutics, Inc. | 2 | $4,412 |
| Lundbeck LLC | 4 | $2,650 |
| Biodelivery Sciences International, Inc. | 1 | $750 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $366 |
| Biogen | 1 | $125 |
| Scynexis, Inc. | 1 | $88 |
| Neurocrine Biosciences, Inc. | 1 | $41 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$45,028
- BOTOX$35,098
- QULIPTA$26,910
- EMGALITY$8,675
- VYEPTI$2,550
- REYVOW$2,500
- ELYXYB - CELECOXIB$750
- NURTEC ODT$720
- RELISTOR$366
- SPINRAZA$125
How this compares
$128,487 in reported general payments places this provider in the 95th percentile of 10,634 family providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other family in San Francisco
- Gabriel SchwartzSan Francisco$166K
- Monica VolzSan Francisco$96K
- Bethany KinseySan Francisco$33K
- Lori RobertsonChino Hills$475K
- Annette ShonLos Angeles$406K
- Lisa HigginsHanford$311K
- Jennifer TougasBakersfield$302K
- Kim SchaferSacramento$288K
- Dawn MeyerSan Diego$270K
- Jennifer KangCerritos$255K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.